Marker Therapeutics Inc.

03/03/2021 | Press release | Distributed by Public on 03/03/2021 06:50

Current report pursuant to Section 13 or 15(d)

Form 8-K filed by MARKER THERAPEUTICS, INC. on 2021-03-03
<_ix3a_header> <_ix3a_hidden> <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:EntityCentralIndexKey'>0001094038 <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt:booleanfalse' name='dei:AmendmentFlag'>false <_ix3a_references> <_link3a_schemaref _xlink3a_href='#mrkr-20210303.xsd' _xlink3a_type='simple'> <_ix3a_resources> <_xbrli3a_context id='From2021-03-03to2021-03-03'> <_xbrli3a_entity> <_xbrli3a_identifier scheme=''>0001094038 <_xbrli3a_period> <_xbrli3a_startdate>2021-03-03 <_xbrli3a_enddate>2021-03-03 <_xbrli3a_unit id='USD'> <_xbrli3a_measure>iso4217:USD <_xbrli3a_unit id='Shares'> <_xbrli3a_measure>xbrli:shares <_xbrli3a_unit id='USDPShares'> <_xbrli3a_divide> <_xbrli3a_unitnumerator> <_xbrli3a_measure>iso4217:USD <_xbrli3a_unitdenominator> <_xbrli3a_measure>xbrli:shares



Washington, D.C. 20549

FORM <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:DocumentType'>8-K


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt:datemonthdayyearen' name='dei:DocumentPeriodEndDate'>March 3, 2021

Date of Report (Date of earliest event reported)

<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:EntityRegistrantName'>MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt-sec:stateprovnameen' name='dei:EntityIncorporationStateCountryCode'>Delaware <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:EntityFileNumber'>001-37939 <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:EntityTaxIdentificationNumber'>45-4497941
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:EntityAddressAddressLine1'>3200 Southwest Freeway

<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:EntityAddressAddressLine2'>Suite 2500

<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:EntityAddressCityOrTown'>Houston, <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt-sec:stateprovnameen' name='dei:EntityAddressStateOrProvince'>Texas

<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:EntityAddressPostalZipCode'>77027
(Address of principal executive offices) (Zip Code)

(<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:CityAreaCode'>713) <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:LocalPhoneNumber'>400-6400

Registrant's telephone number, including area code


(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt:booleanfalse' name='dei:WrittenCommunications'>¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt:booleanfalse' name='dei:SolicitingMaterial'>¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt:booleanfalse' name='dei:PreCommencementTenderOffer'>¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt:booleanfalse' name='dei:PreCommencementIssuerTenderOffer'>¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading
Name of each exchange on which registered
<_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:Security12bTitle'>Common Stock, par value $0.001 per share <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' name='dei:TradingSymbol'>MRKR <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt-sec:exchnameen' name='dei:SecurityExchangeName'>The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company <_ix3a_nonnumeric contextref='From2021-03-03to2021-03-03' format='ixt:booleanfalse' name='dei:EntityEmergingGrowthCompany'>¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

On March 3, 2021, Marker Therapeutics, Inc. (the 'Company') issued a press release entitled 'Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant.' A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 of this Current Report on 8-K (including Exhibit 99.1) is furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release, dated March 3, 2021


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Marker Therapeutics, Inc.
Dated: March 3, 2021 By: /s/ Anthony Kim
Anthony Kim
Chief Financial Officer

Exhibit 99.1

Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant

Topline readout of active disease group in AML trial expected in Q1 2022

Houston, TX - March 3, 2021- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has treated the first patient in the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate. The trial is enrolling patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings.

'We are pleased to have dosed the first patient with MT-401 in our Company-sponsored clinical trial, particularly in a patient population in which there remains a critical unmet need,' said Mythili Koneru, M.D., Ph.D., Chief Medical Officer of Marker Therapeutics. 'Today, adult patients with post-transplant AML have a 25 percent chance of 5-year survival. In various investigator-sponsored Phase 1 trials at the Baylor College of Medicine, our MultiTAA-specific T cell therapies have been generally well-tolerated and demonstrated durable anti-cancer responses across a broad range of cancers-including post-transplant AML. Based on these results, we believe that MT-401 has the potential to become a meaningful treatment option for patients suffering from this disease.'

About the AML Post-Transplant Study

· Designed as a multicenter, Phase 2 trial to be conducted at approximately 20 top cancer centers across the U.S.
· Planned total enrollment of 160 patients:
- 120 patients in the adjuvant disease group, randomized 1:1 to either MT-401 at 90 days post-transplant versus standard of care (observation)
- 40 patients in the active disease group as part of a single arm
· Primary objective of relapse-free survival (RFS) for adjuvant disease group
· Primary objectives of complete response (CR) and duration of complete response (DOCR) for active disease group
· Topline readout of active disease group expected in Q1 2022

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit:

Forward-Looking Statement Disclaimer

This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are 'forward-looking statements.' Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401, as well as clinical trials conducted by our collaborators. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.



Solebury Trout

Brian Korb

(646) 378-2923

[email protected]


Solebury Trout

Amy Bonanno

(914) 450-0349

[email protected]